This award supports multidisciplinary teams investigating the biology, resistance mechanisms, and novel treatments for HER2-mutant non–small cell lung cancer (NSCLC). Projects must integrate clinical, basic, and/or translational work around a central theme and may include analyses of real-world datasets, tumor microenvironment studies, biomarker discovery, and exploration of HER2 amplification or overexpression in conjunction with mutations.
Eligibility Criteria
-
Collaborative “team science” proposals with closely integrated projects spanning clinical, basic, and/or translational research
-
Studies in patients with lung cancer harboring HER2 mutations (and related alterations such as amplification/overexpression)
-
Topics may include, but are not limited to:
-
Biology and mechanisms of HER2-driven tumor progression
-
Primary or secondary resistance to targeted, immune, or combination therapies
-
Real-world data analyses correlating patient demographics with mutation status
-
Immune landscape and tumor microenvironment characterization
-
Biomarker identification for therapy sensitivity
-
Optimization of treatment efficacy and tolerability
-
Funding Details
-
Maximum award: 1,500,000 USD total over 3 years
-
Single application per investigator per grant cycle
Application Process & Deadlines
-
Two-step submission: Letter of Intent (LOI) → Full proposal (invited applicants only)
-
LOI Deadline: July 29, 2025
-
Full Proposal Deadline: November 4, 2025
Further Information
For full RFP details, eligibility criteria, and application instructions, visit the LCRF Grant Application Portal or contact [email protected].